Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023;28(5):452-456.
doi: 10.5863/1551-6776-28.5.452. Epub 2023 Oct 3.

Optimization of Thromboprophylaxis Use in Hospitalized Pediatric Patients Through Implementation of a Venous Thromboembolism Risk Assessment Tool

Affiliations

Optimization of Thromboprophylaxis Use in Hospitalized Pediatric Patients Through Implementation of a Venous Thromboembolism Risk Assessment Tool

Airka Sanchez et al. J Pediatr Pharmacol Ther. 2023.

Abstract

Objective: Venous thromboembolism (VTE) is a leading cause of hospital-acquired morbidity for pediatric patients. Pharmacological thromboprophylaxis increases the risk of adverse events such as bleeding complications. There exists a need for a universal VTE risk assessment tool to aid in thromboprophylaxis prescribing while minimizing the risk of adverse events. The objective of this study is to investigate if implementation of a VTE risk assessment tool is associated with a change in the rate of thromboprophylaxis prescribing.

Methods: This retrospective study evaluated the change in thromboprophylaxis prescribing pre and post implementation of a VTE risk assessment tool. Patients were excluded if they were pregnant, diagnosed with VTE ≤48 hours of admission, presented with VTE symptoms, or if they were diagnosed with multisystem inflammatory syndrome in children (MIS-C) or coronavirus disease (COVID-19).

Results: A total of 186 pediatric patients were included in this study. Thromboprophylaxis was prescribed in 16/93 (17.12%) and 75/93 (80.6%) patients in the pre- and post-implementation group, respectively (95% CI, 0.523-0.745; p < 0.001). No VTE events occurred in either group. Bleeding complications occurred in 3.2% and 7.5% of patients in the pre- and post-implementation groups, respectively. The risk tool was used in 80.6% of patients; providers used the tool correctly in 48% of patients and incorrectly in 52% of patients.

Conclusion: Implementation of a VTE risk assessment tool was associated with a statistically significant change in the rate of thromboprophylaxis prescribing. Incorrect use may be minimized by providing provider reeducation and making modifications to the order set.

Keywords: anticoagulants; pediatrics; pharmacy; retrospective studies; risk assessment; risk factors; venous thromboembolism.

PubMed Disclaimer

Figures

Figure.
Figure.
Facility VTE Risk Assessment Tool.

Similar articles

References

    1. Faustino EV, Raffini LJ. Prevention of hospital-acquired venous thromboembolism in children: a review of published guidelines. Front Pediatr . 2017;5:9. - PMC - PubMed
    1. Monagle P, Cuello CA, Augustine C et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv . 2018;2((22)):3292–3316. - PMC - PubMed
    1. Mahajerin A, Croteau SE. Epidemiology and risk assessment of pediatric venous thromboembolism. Front Pediatr . 2017;5:68. - PMC - PubMed
    1. Jaffray J, Branchford B, Goldenberg N et al. Development of a risk model for pediatric hospital-acquired thrombosis: a report from the Children’s Hospital-Acquired Thrombosis Consortium. J Pediatr . 2021;228:252–259.e1. - PMC - PubMed
    1. Park MY, Fletcher JP, Hoffmann C et al. Prevention of venous thromboembolism through the implementation of a risk assessment tool: a comparative study in medical and surgical patients. Int Angiol . 2018;37((5)):411–418. - PubMed

LinkOut - more resources